News Of The Day
Check Out The Blog For Additional News
News and Updates
March 3 to March 6, 2014
This page offers links to in-depth coverage and media
updates; The Annual Conference on Retroviruses and Opportunistic Infections
Clinical researchers gather to share research focused on HIV/AIDS, and related infectious disease including hepatitis C.
March - Hepatitis C Newsletters
Caffeine dependence tied to physical, emotional problems
In the San Francisco Chronicle an article discusses - caffeine use disorder - a term used to describe dependence on caffeine. Caffeine is ubiquitous in coffee and the idea that the substance can be addictive is hardly new. But for some people, that dependence can be so strong, physically and emotionally, that it becomes problematic.
Faldaprevir- Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients
Today Boehringer Ingelheim announced results from STARTVerso®4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial.
Hepatitis C Drug Price Limiting State Medicaid Approvals
People in Medicaid, the government health plan for the poor, are prime candidates for Gilead’s Sovaldi, which works better and carries fewer side effects than existing therapies. The $84,000 cost for the cure over 12 weeks, the most expensive medicine for the disease, has states from Pennsylvania to Colorado limiting its use to only the sickest patients, according to health officials and private insurers that manage care for Medicaid programs.
Insurers, Medicaid fear multibillion-dollar hepatitis C drug tab
By Caroline Humer
(Reuters) - U.S. health insurers are seeking help from state health officials to foot the bill for a new generation of hepatitis C treatments that could cost the nation $200 billion or more in the next five years.
Hepatitis C virus: Here comes all-oral treatment
In this article, we discuss the results of the trials that established the efficacy and safety of sofosbuvir and simeprevir and led to their FDA approval. We also summarize the importance of these agents and evaluate other direct-acting antivirals currently in the pipeline for HCV treatment.
Simeprevir and Daclatasvir-SVR12 results from a phase IIa study presented at CROI
SVR12 results from a phase IIa study evaluating Simeprevir and Daclatasvir in Hepatitis C patients of genotype 1 have been presented at the 21th Conference on Retroviruses and Opportunistic Infections (CROI)
AbbVie said it will seek U.S. approval next quarter
Hepatitis C- AbbVie to Present Late-breaker PEARL-III Study at the 21st Conference on Retroviruses and Opportunistic Infections
In the PEARL-III trial, treatment-naïve noncirrhotic adults with chronic genotype 1b (GT1b) hepatitis C were treated with an investigational all-oral interferon-free treatment from AbbVie plus ribavirin. After 12 weeks of treatment, sustained virologic response rates reached 99.5%. Even in difficult-to-treat cirrhotic patients, response rates reached 92% to 96%.
The face of liver disease could be your own Canadian Liver Foundation urges Canadians to 'face facts' and recognize own risk factors
Most Canadians are oblivious to their own risks of developing liver disease. Unfortunately, this 'who me?' attitude is leading to a rise in complications and deaths due to advanced liver disease. To help change attitudes, the Canadian Liver Foundation is using Liver Health Month to urge Canadians to recognize that liver disease may have many faces - even their own or someone they love.
All-Oral HCV Regimen Works in 9 Out of 10
BOSTON -- An all-oral, 12-week regimen appears to successfully treat hepatitis C virus (HCV) infection in about 90% of patients, researchers reported here.
Of the 166 treatment-naive patients in the study, 92% achieved a sustained virologic response at 12 weeks (SVR-12) on the combination of the investigative NS5A inhibitor daclatasvir, the protease inhibitor asunaprevir and the non-nucleoside BMS-791325.
PHARMA REFUSES TO ENSURE ACCESS TO LIFESAVING HEPATITIS C TREATMENT AT GLOBAL MEETING
Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies. Yet AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche refused to provide a plan for equitable access to treatment for HCV, a curable infection that kills over 350,000 people each year.
Costly New Hepatitis C Drug Raises Questions About Who Will Pay
There’s a Life-Saving Hepatitis C Drug. But You May Not Be Able To Afford It.
An Update: Treat Hepatitis C Now Or Wait?
A collection of slides which offer SVR rates on both FDA approved and investigational HCV agents, including interferon-free regimens in late stage clinical trials. A few other topics touch on off-label use by combining two newly approved drugs, terminology used to determine treatment response and links to relevant information.
Hepatitis C Infection Tied to Higher Risk of Death From Non-liver Cancers
In addition to their increased risk of death from hepatocellular carcinoma, chronic hepatitis C virus (HCV)-infected patients also have a higher mortality rate from non-Hodgkin lymphoma and pancreatic, rectal, and oral and pharyngeal cancers, according to a new study.
2014 Hepatitis Newsletters
2014: HCV News Digest
2013 : HCV News Digest
The U.S. Food and Drug Administration approved two new oral drugs in 2013 to treat the hepatitis C virus. Johnson & Johnson's protease inhibitor Simeprevir is approved for the treatment of genotype 1, in combination with peginterferon alfa and ribavirin in adults with compensated liver disease, including cirrhosis, who are treatment-naïve or who have failed previous interferon therapy (pegylated or non‑pegylated) with ribavirin. The second drug is Solvadi (sofosbuvir) a polymerase inhibitor approved for people with genotypes 1 and 4, in combination with interferon and ribavirin and for people with genotypes 2 and 3 with ribavirin alone, making it the first interferon free combination approved to treat HCV. Overall cure rates are at 80%, response rates and treatment duration varies, depending on genotype, viral and host factors.
Prescribing information, financial assistance, research articles and important updates
Prescribing and patient information, research and news
Sofosbuvir-ledipasvir alone or with ribavirin
In the November issue of "The Lancet" researchers suggest a fixed-dose combination of sofosbuvir-ledipasvir alone or with ribavirin has the potential to cure most patients with genotype-1 HCV including those with compensated cirrhosis or who have previously failed treatment with protease inhibitors.
Its Back: Daclatasvir Plus Sofosbuvir-Three HCV Clinical Trials Sponsored By Bristol-Myers Squibb
Hepatitis C: 2013 A Year In Review
In this short 2013 review we count down twelve months of news, research and breakthroughs that made a significant difference in the lives of people living with hepatitis C.
Chronic hepatitis C: Treat or wait?
A collection of news articles and research weighing the risks and benefits of treating HCV now vs waiting for future therapies.
Clinical Trial Updates
ClinicalTrials.gov:updated in the last 30 days
To learn more about Hepatitis C virus clinical trials or to find out if a study is enrolling patients in your area, please click here.
Everything You Need To Know Before Starting Treatment
Lucinda K. Porter, RN the author of "Free from Hepatitis C"
new book "Hepatitis C Treatment One Step at a Time" is now available on Amazon
Need To Talk To Someone ?
Help is available, recently "Project Inform" announced the launch of a new national helpline, 877-HELP-4-HEP (877-435-7443), run by and for people affected by hepatitis C.
The helpline operates Monday through Friday 9am to 7pm EST. To learn more, visit www.help4hep.org
New ALF Website
The Hepatitis C: Diagnosis, Treatment, Support website
In addition, questions sent on e-mail to firstname.lastname@example.org will be promptly answered.